Buy Falsolieva 250mg Injection USA – Ernest Oncology Exporter from India

Comprehensive Guide to Falsolieva 250mg Injection: Global Export & Distribution by Ernest Oncology

At Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.), we are an internationally recognized exporter, bulk supplier, and distributor of critical oncology formulations. We specialize in the secure, compliant, and efficient supply of Falsolieva 250mg Injection (Fulvestrant Injection 250mg/5mL) to healthcare providers, hospitals, and pharmaceutical distributors worldwide, with targeted delivery networks in the USA, UK, Australia, and South Africa.

1. Product Information: Falsolieva 250mg Injection

Falsolieva 250mg Injection contains Fulvestrant, which is a hormonal anticancer medicine classified as a Selective Estrogen Receptor Degrader (SERD). It is used to block and degrade estrogen receptors, slowing down the growth of hormone-dependent cancer cells.

Key Product Details

• Composition: Fulvestrant (250 mg / 5 mL per pre-filled syringe or vial).

• Therapeutic Class: Estrogen receptor antagonist / Selective Estrogen Receptor Degrader (SERD).

• Formulation: Injectable solution for intramuscular use.

• Storage Requirement: Store between 2°C and 8°C. Protect from light.

2. Mechanism of Action

Falsolieva functions by binding to estrogen receptors and inhibiting their activity:

• Receptor Downregulation: It competitively binds to the estrogen receptor and downregulates its expression.

• Degradation: Unlike selective estrogen receptor modulators (SERMs), it causes complete degradation of the estrogen receptor, which halts estrogen-driven growth of cancer cells.

3. Therapeutic Indications and Uses

Falsolieva 250mg Injection is indicated for:

• Hormone Receptor Positive (HR+) Breast Cancer: Used in the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer.

• Post-progression Therapy: Often administered after disease progression following antiestrogen therapy (e.g., tamoxifen or aromatase inhibitors).

• Advanced and Metastatic Breast Cancer: Frequently used in combination regimens or as a single agent.

4. Administration and Safety Warnings

Administration

• Route of Administration: Intramuscular (IM) injection (slowly into the gluteal muscle).

• Dosage: The recommended dosage is usually 250 mg administered intramuscularly once a month, with a loading dose given initially.

Side Effects & Precautions

• Common Side Effects: Injection site reactions, nausea, fatigue, headache, joint pain, hot flashes, and back pain.

• Serious Risks: Hepatic impairment/liver dysfunction, thromboembolic events, and bone loss/osteoporosis risk.

• Contraindications: Pregnancy and lactation.